Assembly Biosciences Stock Predictions
Currently predicting for Tue, 31 Jan 2023Trading levels for ASMB
Fibonacci Support & Resistance Levels
| Level | Price | |||
|---|---|---|---|---|
| Resistance | R3 | 1.76 | 3.12 % | |
| R2 | 1.74 | 2.00 % | ||
| R1 | 1.73 | 1.31 % | ||
| Current price: | 1.71 | |||
| Support | S1 | 1.69 | -0.92 % | |
| S2 | 1.68 | -1.61 % | ||
| S3 | 1.66 | -2.73 % |
Accumulated Volume Support & Resistance Levels
| Level | Price | |||
|---|---|---|---|---|
| Resistance | R3 | 0 | . | |
| R2 | 0 | . | ||
| R1 | 0 | . | ||
| Current price | 1.71 | |||
| Support | S1 | 1.37 | -19.88% | |
| S2 | 1.34 | -21.64% | ||
| S3 | 1.30 | -23.98% |
ASMB Predictions History
2 years ago
Solids Metallurgy predicted that
ASMB
for 2020-11-16 is going
$5.62 (0.00%)
3 years ago
NameNotImportant predicted that
ASMB
for 2019-05-06 is going
$14.62 (-13.49%)
3 years ago
NameNotImportant predicted that
ASMB
for 2019-04-29 is going
$15.50 (-3.06%)
3 years ago
NameNotImportant predicted that
ASMB
for 2019-04-22 is going
$18.41 (11.10%)
About Assembly Biosciences
Assembly Biosciences, Inc., a clinical-stage biotechnology company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's lead product candidate is Vebicorvir, which as completed Phase 2 clinical trials to treat patients with chronic HBV infection. It is also developing ABI-H3733 that has completed Phase 1a clinical study, and ABI-4334, which is in pre-clinical tri... ASMB Profile
Top Fintech Company
featured in The Global Fintech Index 2020 as the top Fintech company of the country.
